Serious adverse events in academic critical care research

Cook, Deborah; Lauzier, François; Rocha, Marcelo G.; Sayles, Mary Jane; Finfer, Simon
April 2008
CMAJ: Canadian Medical Association Journal;4/22/2008, Vol. 178 Issue 9, p1181
Academic Journal
The article discusses proposed solutions for more rational reporting of serious adverse events in academic critical care trials of drugs in common use. According to the authors, investigators must clearly describe the serious adverse events that they plan to identify and report in their protocol before commencing the trial. They added that serious adverse events must be largely limited to serious events that are known to result from the study. Moreover, to avoid attributing deaths to serious adverse events related to the study drug as the trial is unfolding, caution must be exercised.


Related Articles

  • Voice of patients missing in adverse event reporting.  // IRB Advisor;May2010, Vol. 10 Issue 5, p53 

    The article discusses research done on adverse event reporting from clinical trials. It references the study "The Missing Voice of Patients in Drug-Safety Reporting," by Ethan Basch, published in the March 11, 2010 issue of the "New England Journal of Medicine." Basch has found that the views of...

  • Communicating the Results of Clinical Research to Participants: Attitudes, Practices, and Future Directions. Shalowitz, David I.; Miller, Franklin G. // PLoS Medicine;May2008, Vol. 5 Issue 5, pe91 

    The authors discuss the available data on the effects of communicating aggregate and individual research results on participants, investigators, and the research enterprise.

  • Trial Registration Numbers Are Underreported in Biomedical Publications. de Wetering, Fleur T. van; Scholten, Rob J. P. M.; Haring, Tamara; Clarke, Michael; Hooft, Lotty // PLoS Clinical Trials;Nov2012, Vol. 7 Issue 11, p1 

    Context: Since September 2005, the International Committee of Medical Journal Editors (ICMJE) has required that randomised controlled trials (RCTs) are prospectively registered in a publicly accessible database. After registration, a trial registration number (TRN) is assigned to each RCT,...

  • Spectrum reports success in prostate cancer drug trial.  // PharmaWatch: Cancer;May2007, Vol. 6 Issue 5, p14 

    The article reports on the success of the satraplatin phase III trial of Spectrum Pharmaceuticals Inc., which confirms that the drug provides both pain relief and improvement of progression-free survival for prostate cancer patients. Dubbed as SPARC trial, it evaluates satraplatin plus...

  • They're Dying to Get In. Bjerklie, David // Time;4/22/2002, Vol. 159 Issue 16, p56 

    Discusses the difficulty of being able to participate in clinical trials in medicine. Benefits of the trials, including substantial doctor-patient interaction; Idea that it is not just the terminally ill who benefit from the attention, but also medically neglected or poorly informed subjects...

  • Efficacy as an Important Facet of "Safety" in Clinical Trials: How Can We Do Our Best for Our Patients? Talbot, George H. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS180 

    Ensuring optimal efficacy is an important facet of patient safety during the conduct of a clinical trial, if, by "safety," we mean the anticipation, prevention, and assessment of any event that can have an unfavorable impact on the enrolled patients. This article addresses what could be termed...

  • Human-subjects research: Trial and error. Ledford, Heidi // Nature;8/2/2007 Supplement, Vol. 448 Issue 7153, p530 

    The article focuses on the efforts of researchers to come up with alternatives to institutional review boards (IRBs) that would determine if a proposed research is ethically sound. It mentions the problems encountered by most researchers in many countries due to the presence of a complex network...

  • "We saw human guinea pigs explode" Stobbart, L; Murtagh, MJ; Rapley, T; Ford, GA; Louw, SJ; Rodgers, H // BMJ: British Medical Journal (International Edition);3/17/2007, Vol. 334 Issue 7593, p566 

    This article focuses on the media coverage of adverse drug effects in the "first in man" phase of the clinical trial of TGN1412, a monoclonal antibody in development by TeGenero for the treatment of diseases involving T cells. Clinical subjects experienced serious side effects within hours of...

  • Clinical Trial Design and Selected Drug Safety Issues for Antibiotics Used to Treat Community-Acquired Pneumonia. Psaty, Bruce M. // Clinical Infectious Diseases;12/1/2008 Supplement 3, Vol. 47, pS176 

    High-quality evaluations of both efficacy and safety are essential to characterize the risk-benefit profile of antibiotics. The current US Food and Drug Administration guidelines on trial design for community-acquired pneumonia have several weaknesses, including the failure to insist on the use...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics